We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





SARS-CoV-2 Variant Test Breakthrough to Improve Tracking and Understanding of Emerging COVID-19 Mutations

By LabMedica International staff writers
Posted on 15 Jun 2021
A new highly reliable COVID-19 variant test can accurately identify known SARS-CoV-2 variants and aid in the discovery of novel variants.

Aventus Health (Orlando, FL, USA) has launched its new COVID-19 Variant Test designed to reliably identify known SARS-CoV-2 variants and the discovery of novel variants. More...
Aventus’ COVID-19 Variant Test was developed through an innovative application of its Next-Generation Sequencing (NGS) technology and the cutting-edge, laboratory-developed assay that together break down the sequence of base pairs that constitute the genetic makeup of the various strains of corona virus. The result is a reliable test result that can advance the study, tracking and understanding of emerging COVID-19 variants and their potential impact on public health.

Aventus offers a suite of COVID-19 testing services and will now include reflex testing-to-NGS on all Aventus’ RT-PCR patient tests that return a positive result in order to identify currently known variants as well as those yet to be discovered. There is no additional cost or special instructions for individuals using Aventus’ tests.

According to Aventus’ Medical Director, Michelle Taylor, MD, variant testing is complicated and not widely available because it requires scientists use a process called genomic sequencing, which requires advanced and expensive technology and diagnostic expertise. “The instruments Aventus uses are manufactured for the highest sensitivity genetic sequencing capabilities on the market,” Dr. Taylor noted. “They are critical to our mission of helping healthcare providers leverage innovations in genomics and diagnostics to deliver affordable and effective personalized and precision medicine. Addressing the need for COVID-19 and variant testing and diagnostics is a natural fit for us.”

“This is a breakthrough in healthcare that will greatly aid the general public in better understanding the different strains of COVID-19. It will allow us to know what strain an individual has and even get ahead of the curve on any new strains that may develop,” added Oliver Dawoud, Aventus CEO.


Related Links:
Aventus Health


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.